Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance

Last updated: January 23, 2024
Sponsor: Nutricia Nutrition Clinique
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy

Treatment

Ketocal

Clinical Study ID

NCT06075485
2023-A01073-42
  • Ages 5-18
  • All Genders

Study Summary

This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy.

This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Infants from 5 months and children up to 17 years of age (maximum 18 years minus 1day).
  • With drug-resistant epilepsy according to ILAE (International League Against Epilepsy)criteria: persistence of epileptic seizures after failure of two appropriateantiepileptic drugs tried consecutively or in well-tolerated combination.
  • Indication for CR by a physician.
  • Parents (or legal guardians) able to set up and follow the diet, assessed during ajoint doctor-dietician consultation.
  • Written authorization from one (or both) parents or the child's legal representativeto collect personal information about their child.
  • Affiliation of the infant/child with the social security system.

Exclusion

Exclusion Criteria:

  • Contraindication to ketogenic diet at initial assessment.
  • Children already on a ketogenic diet.
  • Parenteral nutrition.
  • Concurrent prescription of other foodstuffs intended for special medical purposes (DADFMS) such as KetoVie or Keyo.
  • Protected legal representative (under legal protection, or deprived of liberty byjudicial or administrative decision).
  • Legal representative not covered by a social security scheme.
  • Legal representative unable to understand study protocol. Ancillary study eligibility criteria :
  • Patients included in the study.
  • Continued on the ketogenic diet for at least 2 months.
  • Having consented to participate in the ancillary study.

Study Design

Total Participants: 133
Treatment Group(s): 1
Primary Treatment: Ketocal
Phase:
Study Start date:
January 15, 2024
Estimated Completion Date:
June 30, 2026

Study Description

NUTRICIA has developed the KetoCal® range (4:1 and 3:1), a food for special medical purposes (DADFMS), to help healthcare professionals and patients establish and maintain a CR. KetoCal® 4:1 features a 4:1 ratio of fat to (carbohydrate + protein), while containing vitamins, minerals, trace elements and fiber. Similarly, KetoCal® 3:1 has a 3:1 ratio of lipids / (carbohydrates + proteins), while containing vitamins, minerals, trace elements and fiber. The KetoCal® range can be consumed orally, as a drink after dilution in hot water, incorporated as an ingredient in a recipe or administered by enteral feeding tube.

The KEOPS study is designed to gather real-life data on the therapeutic value of using the KetoCal® range in the management of drug-resistant epilepsy in infants (from 5 months) and children up to 18 years of age. Patients will be managed according to standard care practices. Initiation of ketogenic dieting will be at the investigator's discretion during the child's hospitalization.

Connect with a study center

  • CHRU Lille

    Lille, 59037
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.